Earnings Releases·Nov 10, 2026, 7:31 AM ET

Arbutus Biopharma — Third Quarter 2026 Earnings Summary

Revenue declined to $0.3 million from $0.5 million year-over-year due to lower Alnylam royalties, while net income swung to $59.1 million ($0.30/share) from a $7.7 million loss in the prior year period.
Cash and marketable securities increased to $337.5 million as of September 30, 2026, driven by a $178.4 million Moderna settlement payment and a $67.3 million Genevant dividend, with operating cash flow turning positive at $225.7 million for the nine-month period.
The FDA lifted the clinical hold on AB-101, enabling resumed U.S. development, while Phase 2a data for imdusiran (AB-729) demonstrated functional cure in eight chronic hepatitis B patients.
Management executed a $230 million capital return via a tender offer in early October 2026, purchasing and cancelling 46 million shares, and continues to pursue global LNP patent enforcement against Pfizer/BioNTech.
A contingent payment of up to $1.3 billion remains pending the outcome of the November 5, 2026, Moderna §1498 Appeal oral argument.